Cargando…
Uptake of new antidiabetic medicines in 11 European countries
BACKGROUND: Several new antidiabetic medicines (GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors) have been approved by the European Medicines Agency since 2006. The aim of this study was to evaluate the uptake of new antidiabetic medicines in European countries over a 10-year period...
Autores principales: | Mardetko, Nika, Nabergoj Makovec, Urska, Locatelli, Igor, Janez, Andrej, Kos, Mitja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235847/ https://www.ncbi.nlm.nih.gov/pubmed/34172020 http://dx.doi.org/10.1186/s12902-021-00798-3 |
Ejemplares similares
-
Improved adherence with Medicines Use Review service in Slovenia: a randomized controlled trial
por: Nabergoj Makovec, Urška, et al.
Publicado: (2021) -
Influence of generic reference pricing on medicine cost in Slovenia: a retrospective study
por: Marđetko, Nika, et al.
Publicado: (2018) -
Cardiovascular morbidity and mortality in patients with type 2 diabetes using novel antidiabetic medicines as add-on therapy: an observational real-world study
por: Zerovnik, Spela, et al.
Publicado: (2021) -
Pharmacist-led clinical medication review service in primary care: the perspective of general practitioners
por: Nabergoj Makovec, Urska, et al.
Publicado: (2023) -
Decision-making criteria for medicine reimbursement in Slovenia: an expert panel discussion
por: Detiček, Andreja, et al.
Publicado: (2018)